About our research group/lab
Two main objectives of our epidemiological studies are:
- counselling and treatment of patients with hereditary breast and/or ovarian cancer
- late effects of breast cancer treatment
Origin and development
In the mid 1990s the multidisciplinary working group “Hereditary Cancer” was established at our institute – the same period that BRCA1 and BRCA2 germline mutations were first identified.
Initially, study results were mainly obtained through genetic, epidemiologic and oncologic data registered locally. Early studies contributed to a better insight into the efficacy and side effects of preventive measures, the characteristics and clinical course of hereditary breast and ovarian cancer and the preferences and decisions of women regarding genetic testing.
Over the last 10 years, we have focused more on collaboration with fellow researchers outside the institute; together we have realized much larger and more powerful national datasets available for analysis, both in the hereditary as in the general breast cancer setting. With the broadening of the research scope, the name of the group changed into “Cancer Epidemiology”.
In hereditary cancer, we work on prognosis of BRCA1/2 associated breast cancer and ovarian cancer by using national HEBON data; we are further in the lead of establishing a national cohort of breast cancer families with a CHEK2 1100delC mutation; prospective data on breast cancer incidence are urgently needed for better risk stratification by age and family history, and for improved follow-up regimens and counselling regarding preventive measures.
Late effects of treatment
Studies on late effects of breast cancer treatment have become increasingly important over the last decades due to improving survival rates of breast cancer. In a joint initiative with the Netherlands Cancer Institute, risks of cardiovascular disease and second breast cancers have been established.
We developed a comprehensive risk model for second breast cancer by identifying and integrating all known risk/protective factors. Use of the final version will be most helpful in decision making on preventive measures and follow-up procedures for patients and their clinicians.
We participate in the BRAGATSTON study led by UMC Utrecht, investigating the predictive value of coronary artery calcifications measured on radiotherapy planning CT scans for risk of cardiovascular disease in breast cancer patients.
Late effects in hereditary setting
A perfect example in which both main objectives come together is the HARMONY study. Based on the nationwide HEBON cohort, we investigate long-term health effects of premenopausal risk-reducing salpingo-oophorectomy in women at high risk of ovarian cancer. The HARMONY study is performed in close collaboration with the Netherlands Cancer Institute and Radboud UMC Nijmegen. Study objectives concern breast cancer-specific mortality, cardiovascular status, bone mineral density, cognition and quality of life.
On the international level, we established and continued close collaboration with several consortia (Breast Cancer Association Consortium (BCAC); Consortium of Investigators of Modifiers of BRCA1/2 (CIMBA) for many years by now.
The large datasets realized by these collaborative research groups have enabled to gain important new insights into genetic, environmental and lifestyle factors associated with breast cancer risk.
Based on this information, better comprehensive risk models have been developed that will have great impact not only on the counseling advice in high-risk families but also on the screening guidelines in the general female population.
Risk prediction, screening and therapy of breast cancer in women from CHEK2 c.1100delC families in the Netherlands.
Favorable and unfavorable effects of risk-reducing salpingo-oophorectomy (RRSO) in women at high genetic risk of ovarian cancer.
Risk management of contralateral breast cancer; development and validation of an online decision aid for physicians and patients.
The sequel to the Angelina Jolie effect: the impact of bilateral risk-reducing mastectomy on survival and cancer-related anxiety in BRCA1/2 mutation carriers.
Akdeniz D, van Barele M, Heemskerk-Gerritsen BAM, Steyerberg EW, Hauptmann M; HEBON Investigators, van de Beek I, van Engelen K, Wevers MR, Gómez García EB, Ausems MGEM, Berger LPV, van Asperen CJ, Adank MA, Collée MJ, Stommel-Jenner DJ, Jager A, Schmidt MK, Hooning MJ. Effects of chemotherapy on contralateral breast cancer risk in BRCA1 and BRCA2 mutation carriers: A nationwide cohort study. Breast. 2022 Feb;61:98-107.
van Barele M, Heemskerk-Gerritsen BAM, Louwers YV, Vastbinder MB, Martens JWM, Hooning MJ, Jager A. Estrogens and progestogens in triple negative breast cancer : Do they harm? Cancers, Vol. 13, No. 11, 2506, 21.05.2021.
Kramer I, Hooning MJ, Mavaddat N, Hauptmann M, Keeman R, Steyerberg EW, Giardiello D, Antoniou AC, Pharoah PDP, Canisius S, Abu-Ful Z, Andrulis IL, Anton-Culver H, Aronson KJ, Augustinsson A, Becher H, Beckmann MW, Behrens S, Benitez J, Bermisheva M, Bogdanova NV, Bojesen SE, Bolla MK, Bonanni B, Brauch H, Bremer M, Brucker SY, Burwinkel B, Castelao JE, Chan TL, Chang-Claude J, Chanock SJ, Chenevix-Trench G, Choi JY, Clarke CL; NBCS Collaborators, Collée JM, Couch FJ, Cox A, Cross SS, Czene K, Daly MB, Devilee P, Dörk T, Dos-Santos-Silva I, Dunning AM, Dwek M, Eccles DM, Evans DG, Fasching PA, Flyger H, Gago-Dominguez M, García-Closas M, García-Sáenz JA, Giles GG, Goldgar DE, González-Neira A, Haiman CA, Håkansson N, Hamann U, Hartman M, Heemskerk-Gerritsen BAM, Hollestelle A, Hopper JL, Hou MF, Howell A; ABCTB Investigators; kConFab Investigators, Ito H, Jakimovska M, Jakubowska A, Janni W, John EM, Jung A, Kang D, Kets CM, Khusnutdinova E, Ko YD, Kristensen VN, Kurian AW, Kwong A, Lambrechts D, Le Marchand L, Li J, Lindblom A, Lubiński J, Mannermaa A, Manoochehri M, Margolin S, Matsuo K, Mavroudis D, Meindl A, Milne RL, Mulligan AM, Muranen TA, Neuhausen SL, Nevanlinna H, Newman WG, Olshan AF, Olson JE, Olsson H, Park-Simon TW, Peto J, Petridis C, Plaseska-Karanfilska D, Presneau N, Pylkäs K, Radice P, Rennert G, Romero A, Roylance R, Saloustros E, Sawyer EJ, Schmutzler RK, Schwentner L, Scott C, See MH, Shah M, Shen CY, Shu XO, Siesling S, Slager S, Sohn C, Southey MC, Spinelli JJ, Stone J, Tapper WJ, Tengström M, Teo SH, Terry MB, Tollenaar RAEM, Tomlinson I, Troester MA, Vachon CM, van Ongeval C, van Veen EM, Winqvist R, Wolk A, Zheng W, Ziogas A, Easton DF, Hall P, Schmidt MK. Breast Cancer Polygenic Risk Score and Contralateral Breast Cancer Risk. Am J Hum Genet. 2020 Nov 5;107(5):837-848.
Giardiello D, Steyerberg EW, Hauptmann M, Adank MA, Akdeniz D, Blomqvist C, Bojesen SE, Bolla MK, Brinkhuis M, Chang-Claude J, Czene K, Devilee P, Dunning AM, Easton DF, Eccles DM, Fasching PA, Figueroa J, Flyger H, García-Closas M, Haeberle L, Haiman CA, Hall P, Hamann U, Hopper JL, Jager A, Jakubowska A, Jung A, Keeman R, Kramer I, Lambrechts D, Le Marchand L, Lindblom A, Lubiński J, Manoochehri M, Mariani L, Nevanlinna H, Oldenburg HSA, Pelders S, Pharoah PDP, Shah M, Siesling S, Smit VTHBM, Southey MC, Tapper WJ, Tollenaar RAEM, van den Broek AJ, van Deurzen CHM, van Leeuwen FE, van Ongeval C, Van't Veer LJ, Wang Q, Wendt C, Westenend PJ, Hooning MJ, Schmidt MK. Prediction and clinical utility of a contralateral breast cancer risk model. Breast Cancer Res. 2019 Dec 17;21(1):144.
Heemskerk-Gerritsen BAM, Jager A, Koppert LB, Obdeijn AI, Collée M, Meijers-Heijboer HEJ, Jenner DJ, Oldenburg HSA, van Engelen K, de Vries J, van Asperen CJ, Devilee P, Blok MJ, Kets CM, Ausems MGEM, Seynaeve C, Rookus MA, Hooning MJ. Survival after bilateral risk-reducing mastectomy in healthy BRCA1 and BRCA2 mutation carriers. Breast Cancer Res Treat. 2019 Oct;177(3):723-733.
Collaborations within Erasmus MC
We work in close collaboration with other specialisms/groups involved in the care and research of breast and ovarian cancer:
- Clinical Genetics
- Breast Cancer Genomics
- Surgical Oncology
- Radiation Oncology
- Gynecological Oncology
Collaborations outside of Erasmus MC
- HEBON: Netherlands Collaborative Group on Hereditary Breast and Ovarian Cancer
- Netherlands Cancer Institute, Molecular Pathology: prof.dr. Marjanka Schmidt
- BCAC: Breast Cancer Association Consortium
- CIMBA: Consortium of Investigators of Modifiers of BRCA1/2
Funding & Grants
We receive funding from the following organizations:
Group leader: Maartje J. Hooning, PhD
- Annette B.A.M. Heemskerk-Gerritsen, PhD, Postdoc
- Elizabeth Loehrer, PhD, Postdoc
- Agnes Jager, MD, PhD, Medical Oncologist
- Selin Oztekin, Research Master student in Health Sciences (NIHES)
- Yvonne Unkel, Datamanager
- Saskia Pelders, ir, Datamanager
- Delal Akdeniz, MD, PhD student
- Mark van Barele, MD, PhD student
- Maartje A.C. Schreurs, ir, PhD student
Contact us? Mail to our secretary.